Anne Laprie

Professor of Radiation Oncology @IUCTOncopoleICR #Radonc MR in RT, molecular imaging , AYA & #ChildhoodCancer #pedcsm #ayacsm Clinical trials . #RadOncWomen

[SIOP International @WorldSIOP]

🚨 Exciting News! 🚨 The #ARIAGuide Global Initiative has launched its first Adapted Management Guideline (AMG) for #HodgkinLymphoma! 🎉🌍

This marks a major step toward resource-adapted, global guidelines for childhood cancer treatment: https://t.co/PM4pwR0x77 💻📚

[Anne Laprie @anne_laprie]

Gracias a @somera_mx , por invitarme a hablar este noche de #radioterapia pediatrica del #neuroblastoma . @intpros1 @SIOPEurope @IUCTOncopole @umbertoricardi
Gracias guadalupe Garcia Vega y Beatriz Aliacer

[Anne Laprie @anne_laprie]

Published in @NeuroOnc #Spectroscopy guided multicentric phase 3 trial of #radiotherapy dose-painting for newly diagnosed #glioblastoma
👉180 patients
👉72 Gy boost vs. 60Gy.
👉No added toxicity no OS /EFS improvement .
👉but 38 months OS with 72Gy if MGMT+
👉prospective QC

[SNO @NeuroOnc]

A randomized phase III trial of metabolic imaging-guided dose escalation of radio-chemotherapy in patients with newly diagnosed glioblastoma (SPECTRO GLIO trial)
https://t.co/tTt6NVvXgp

[David Pasquier @David__Pasquier]

Delighted to publish the very long term results of our phase II SBRT boost in intermediate risk prostate cancer.
Very low rate of G2+ late GU toxicity

A Multicenter Phase 2 Study of Ultrahypofractionated Stereotactic Boos... https://t.co/WTL3T2FhJI

[Anne Laprie @anne_laprie]

Congrats @CPasquierRT ( so proud of our resident !) and @jnt_khalifa for this interesting paper on the impact of #radiotherapy on host immune structures in #nsclc.

[Jonathan Khalifa 🎗️ @jnt_khalifa]

🚨🔥Hot off the press🔥 Our study on the impact of radiation to host immune structures during chemoradiation > durva in patients with st.III non small cell lung cancer is out in @FrontOncology #nsclc 🫁⚡️
🧵 1/5

https://t.co/O6tTQD5lqV

[Anne Laprie @anne_laprie]

@PDBrownOnc thanks @PDBrownOnc
also
- centralized integration of MR spectroscopic imaging - -and prospective quality control, what we believe should be a robust dose-painting trial

[Drew Moghanaki @DrewMoghanaki]

I know at least a dozen radiation oncologists who have worried for decades that IMRT would increase the risk of secondary cancers compared to conventional 3DCRT. A SEER-linked Mediare study of 65,235 patients with at least 2 years of survival now tells us this. #radonc

[Anne Laprie @anne_laprie]

@IUCTOncopole @Institut_cancer very humbled and grateful to @Institut_cancer for funding with 1 220 000 euros the THINK project to fuel our battle against the frequent cognitive sequelae of #survivors of brain #childhoodcancer.
#ChildhoodCancerAwareness
#internationalchildhoodcancerday #ICCD2023

[SIOPE 🎗️ @SIOPEurope]

Today is #InternationalChildhoodCancerDay🎗️
Together, we can make life-saving differences to #childhoodcancer patients and #survivors 👉 Cure More, Cure Better 💪
Help raise #ChildhoodCancerAwareness, like & share this video 🙏
#SIOPEurope25Yrs

[Jacky Lam @JackyWKLam]

A global collaborative effort to push forward #EBV based #screening for #nasopharyngeal #cancer 💪🏼💪🏼💪🏼 @ajacobmiller @DrMLChua @Zhiwei_Liu @Qle_stanford and so many more!!! https://t.co/VEWkKiBMev

[ESTRO @ESTRO_RT]

Clinical and Translational Radiation Oncology has received its first Impact Factor of 4.739!👏Thank you to all submitting authors and congratulations to the editorial team and editors in chief @PBlanchardMD & Daniel Zips👉 https://t.co/K3oM8D2z9h
#Radonc #Oncology #OpenAccess

[Stanislav (Stas) Lazarev, MD @StasLazarev]

⚡️The question of residual disease boost in high-risk
#neuroblastoma patients remains open and is being investigated on HRNBL2 study.

What a great #SIOP2021 talk by Dr. @anne_laprie from @IUCTOncopoleICR ! 👏👏👏

@WorldSIOP @intpros1 @IPSO_PedSurgOnc

[OncoAlert @OncoAlert]

If you haven't read the editorial on @ASCO DailyNews
Sexual&Gender-Based Harassment in Oncology👩‍⚕️👨‍⚕️

by @DrChoueiri @drdonsdizon @NarjustDumaMD @DrSGraff @marklewismd @DrMarkham & @weoncologists
Here's a2⃣min clip on how to end this culture of harassment
https://t.co/MhnSgzqOov

[arjun sahgal @SahgalArjun]

More from the #elekta CORE group and this paper led by Kristin Redmond @JohnsHopkins detailing outcomes for spine and non spine oligomet patients. Excellent local control observed with mature followup. However, we need a rct like sc24 but for non spine bone mets to push forward.

[Justin Baker @justinnbaker]

GREAT advice! Self-care is NOT selfish! @StJudeResearch

[International Hospital Federation @IHF_FIH]

Unicancer's session will present its flagship programs ESME, Europe's largest source of real-world oncology data; Consore, a powerful search engine for health big data; other projects such as UNIBASE, OncoSNIPE, Precision Predict, DeepSarc and Ependymomics https://t.co/zZomTQqznZ

[Anne Laprie @anne_laprie]

#PediatricCancerAwarenessMonth #Pedcsm Pediatric #Radonc #SeptembreenOr

[Collectif Gravir @CollectifGravir]

C'est parti pour le mois de #SeptembreenOr et les mobilisations contre les cancers des enfants et des jeunes. L'occasion pour chacun de témoigner de son soutien aux enfants, aux parents, aux associations, aux professionnels de santé, aux chercheurs... 🙏��️

[Anne Laprie @anne_laprie]

@jebibault @Univ_Paris congrats Jean-Emmanuel , well deserved !
welcome among the Radiation Oncology professors !

[Pierre Blanchard, MD @PBlanchardMD]

Design, endpoints, statistical analysis, surrogates, clinical value, subgroups, basket trials, reporting...

All the important points for critical appraisal of phase III trials elegantly presented by Prof Ian Tannock.

Listen on @myESMO website here: https://t.co/d9i2LubyD8

[SIOPE 🎗️ @SIOPEurope]

Yes, you´ve read it right! Childhood cancer is the cause of 6000 children and young people in Europe dying every year. Many of those who survive suffer long-term side effects due to their treatments.

🎗 #supportchildrenwithcancer #ChildhoodCancerAwarenessMonth #wecareweshare